AllAnalyst Report
Morningstar•January 11, 2021
Morningstar•January 11, 2021Exact Sciences Corporation: Launching on Exact Sciences With $76 FVE; Inexact Liquid Biopsy Potential Informs No-Moat Rating
Summary
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Ex
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: DexCom, Inc.Apr 26, 2024 •
DXCM
- Analyst Report: Laboratory Corporation of America HoldingsApr 25, 2024 •
LH
- Analyst Report: Quest Diagnostics IncorporatedApr 24, 2024 •
DGX
- TRUP: Raising target price to $20.00Apr 24, 2024 •
TRUP, DXCM
- DXCM: Lowering target price to $141.00Apr 24, 2024 •
DXCM
Analyst Profile
Aaron Degagne
Equity AnalystAaron DeGagne is an equity analyst, financial services, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and conducts general research on the global financial-services sector.Before joining Morningstar in 2017, DeGagne was an accounting intern for Campgroup and completed two lending-group internships with RBC Capital Markets.DeGagne holds a Bachelor of Business Administration in finance from the University of Notre Dame’s Mendoza College of Business.